| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Therapeutic response in phase I trials of antineoplastic agents.
|
Cancer Treat Rep
|
1986
|
1.91
|
|
2
|
The impact of patient management guidelines on the care of breast, colorectal, and ovarian cancer patients in Italy.
|
Med Care
|
1991
|
1.62
|
|
3
|
Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica.
|
Ann Oncol
|
1995
|
1.54
|
|
4
|
Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interventi in Oncologia, and the Japanese Foundation for Cancer Research.
|
Lancet
|
1998
|
1.46
|
|
5
|
The impact of cancer treatment guidelines on actual practice in Italian general hospitals: the case of ovarian cancer.
|
Ann Oncol
|
1990
|
1.40
|
|
6
|
Etoposide (VP-16-213). Current status of an active anticancer drug.
|
N Engl J Med
|
1985
|
1.23
|
|
7
|
Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe?
|
Ann Oncol
|
2013
|
1.16
|
|
8
|
Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin.
|
Br J Cancer
|
2012
|
1.06
|
|
9
|
Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience'.
|
Ann Oncol
|
2011
|
1.00
|
|
10
|
GIVIO-SITAC 01: A randomized trial of adjuvant 5-fluorouracil and folinic acid administered to patients with colon carcinoma--long term results and evaluation of the indicators of health-related quality of life. Gruppo Italiano Valutazione Interventi in Oncologia. Studio Italiano Terapia Adiuvante Colon.
|
Cancer
|
1998
|
1.00
|
|
11
|
Relation of preclinical toxicology to findings in early clinical trials.
|
Cancer Treat Rep
|
1986
|
0.94
|
|
12
|
Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex.
|
Ann Oncol
|
2000
|
0.93
|
|
13
|
Tolerance to antineoplastic agents in children and adults.
|
Cancer Treat Rep
|
1985
|
0.92
|
|
14
|
Clinical drug development: an analysis of phase II trials, 1970-1985.
|
Cancer Treat Rep
|
1987
|
0.92
|
|
15
|
Amsacrine-associated cardiotoxicity: an analysis of 82 cases.
|
J Clin Oncol
|
1986
|
0.91
|
|
16
|
Steroid receptors in epithelial ovarian carcinoma: relation to clinical parameters and survival.
|
Cancer Res
|
1988
|
0.91
|
|
17
|
Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors.
|
Ann Oncol
|
2006
|
0.88
|
|
18
|
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.
|
Eur J Cancer
|
2009
|
0.87
|
|
19
|
Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule.
|
Ann Oncol
|
2007
|
0.86
|
|
20
|
Treating childhood acute lymphoblastic leukaemia (ALL): summary of ten years' experience in Italy. ALL Steering Committee of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP).
|
Med Pediatr Oncol
|
1989
|
0.84
|
|
21
|
Clinical development of anticancer agents--a National Cancer Institute perspective.
|
Cancer Treat Rep
|
1984
|
0.81
|
|
22
|
Teniposide: a review of 12 years of experience.
|
Cancer Treat Rep
|
1984
|
0.81
|
|
23
|
Tiazofurin: a new antitumor agent.
|
Invest New Drugs
|
1984
|
0.79
|
|
24
|
Patterns of care and survival in non small cell lung cancer: 15 years' experience in a general hospital.
|
Tumori
|
1994
|
0.79
|
|
25
|
Flow cytometric analysis of DNA content in human ovarian cancers.
|
Br J Cancer
|
1989
|
0.79
|
|
26
|
Breast cancer surgery in 30 Italian general hospitals.
|
Eur J Surg Oncol
|
1993
|
0.78
|
|
27
|
Early phase pharmacokinetics of doxorubicin (adriamycin) in plasma of cancer patients during single- or multiple-drug therapy.
|
Cancer Treat Rep
|
1981
|
0.78
|
|
28
|
Process and outcome of care for patients with ovarian cancer.
|
Br Med J (Clin Res Ed)
|
1985
|
0.78
|
|
29
|
Fluorouracil and folinic acid in colon cancer. IMPACT Investigators.
|
Lancet
|
1995
|
0.76
|
|
30
|
Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin.
|
Eur J Cancer
|
2004
|
0.76
|
|
31
|
Association of severe and fatal infections and treatment with pentostatin.
|
Cancer Treat Rep
|
1986
|
0.76
|
|
32
|
Efficacy of intraportal infusion for colon cancer: a fair assessment?
|
J Clin Oncol
|
1991
|
0.75
|
|
33
|
Efficacy, semantic and chemotherapy in advanced NSCLC.
|
Ann Oncol
|
1994
|
0.75
|
|
34
|
Prognostic factors analysis in clinical oncology: handle with care.
|
Ann Oncol
|
1991
|
0.75
|
|
35
|
Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies.
|
Br J Cancer
|
2012
|
0.75
|
|
36
|
Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results.
|
Cancer Treat Rev
|
1991
|
0.75
|
|
37
|
A proposal for a new approach to intergroup cancer trials.
|
Eur J Cancer
|
1995
|
0.75
|
|
38
|
Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin.
|
Recent Results Cancer Res
|
1982
|
0.75
|
|
39
|
Trends in patterns of care for breast cancer in Italy (1979-1987).
|
Tumori
|
1990
|
0.75
|
|
40
|
Cancer drug development in Europe: a selection of new agents under development at the European Drug Development Network.
|
Cancer Invest
|
2003
|
0.75
|
|
41
|
Randomized single-agents trials in recurrent epithelial ovarian cancer.
|
Int J Gynecol Cancer
|
2005
|
0.75
|
|
42
|
Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
|
Cancer Treat Rep
|
1986
|
0.75
|
|
43
|
VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma.
|
Cancer Chemother Pharmacol
|
1982
|
0.75
|
|
44
|
Minimal guidelines for the monitoring of early clinical trials (phase I-II) in Europe under CRC/EORTC/NCI joint agreement.
|
Eur J Cancer
|
1992
|
0.75
|
|
45
|
Vincristine and bleomycin do not interfere with infusional plasma levels of methotrexate.
|
Eur J Cancer
|
1981
|
0.75
|
|
46
|
[Comorbidity and the physician's decision: the case of undertreatment in care of breast tumors].
|
Epidemiol Prev
|
1994
|
0.75
|
|
47
|
The phase II trial.
|
Cancer Treat Rep
|
1985
|
0.75
|
|
48
|
Spiromustine: a new agent entering clinical trials.
|
Invest New Drugs
|
1983
|
0.75
|
|
49
|
Phase II study of cyclophosphamide and hexamethylmelamine in non-oat cell bronchogenic carcinoma.
|
Cancer Treat Rep
|
1981
|
0.75
|
|
50
|
Plasma levels of cyclophosphamide in patients under polychemotherapeutic regimens.
|
Biomedicine
|
1980
|
0.75
|
|
51
|
Early ovarian cancer and the icon trials.
|
Eur J Cancer
|
1992
|
0.75
|
|
52
|
Bleomycin, vincristine, and methotrexate (BOM) in squamous cell carcinoma of the lung: a phase II study.
|
Cancer Treat Rep
|
1981
|
0.75
|
|
53
|
Bis-diketopiperazine derivatives in clinical oncology: ICRF-159.
|
Cancer Clin Trials
|
1980
|
0.75
|
|
54
|
Quality of care of colorectal cancer patients in general hospitals: diffusion and impact of management guidelines.
|
Tumori
|
1990
|
0.75
|